Ficha

oai_dc

Descargar XML

<?xml version="1.0" encoding="UTF-8" ?>

1. <oai_dc:dc schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">

   1. <dc:title>Analysis of medicine advertisement produced in Brazil</dc:title>

   2. <dc:creator>Badaró Trindade, Angela C.</dc:creator>

   3. <dc:creator>Wzorek, Lorilei de Fátima</dc:creator>

   4. <dc:creator>Correr, Cassyano J.</dc:creator>

   5. <dc:creator>Pontarolo, Roberto</dc:creator>

   6. <dc:subject>Advertising</dc:subject>

   7. <dc:subject>Periodicals</dc:subject>

   8. <dc:subject>Drug Industry</dc:subject>

   9. <dc:subject>Brazil</dc:subject>

   10. <dc:description>Objective: To analyze the compliance of drug advertisements with regulations in Brazil, subject to Resolution RDC No. 102/2000 since 2000, which abides by the WHO¿s (World Health Organization) Ethical Criteria for Medicinal Drug Promotion, published in 1988. Methods: Drug advertisements running within the period of October 2002 to October 2003 were collected and recorded. Media sources included various AM and FM radio stations, television channels, newspapers, and magazines, as well as printed material distributed in doctors¿ offices, hospitals, drugstores, conferences, billboards, and bus doors. All sources were located in Curitiba City, Brazil, and its surrounding area. Advertisement content was analyzed according to a conformity checklist prepared based on the legal requirements of RDC No. 102/00. Results: A total of 827 advertisements for 517 different products, 83.91% regularly registered as medicinal drugs and 16.09% unregistered products that should be registered according to the Brazilian regulations, were recorded and collected. Approximately 74.73% of the advertisements did not comply with regulations; on average, such advertisements had 4.6 infractions each. Conclusions: The results of this research suggest that RDC No. 102/00 is not followed, which strengthens the need to adopt new forms of regulation to prohibit excesses of the pharmaceutical industry and to protect the population from abusive and misleading drug advertising.</dc:description>

   11. <dc:publisher>Centro de Investigaciones y Publicaciones Farmacéuticas</dc:publisher>

   12. <dc:date>2007</dc:date>

   13. <dc:type>text (article)</dc:type>

   14. <dc:format>application/pdf</dc:format>

   15. <dc:identifier>https://dialnet.unirioja.es/servlet/oaiart?codigo=2362776</dc:identifier>

   16. <dc:identifier>(Revista) ISSN 1886-3655</dc:identifier>

   17. <dc:source>Pharmacy Practice (Granada), ISSN 1886-3655, Vol. 5, Nº. 3, 2007, pags. 105-108</dc:source>

   18. <dc:language>eng</dc:language>

   19. <dc:rights>LICENCIA DE USO: Los documentos a texto completo incluidos en Dialnet son de acceso libre y propiedad de sus autores y/o editores. Por tanto, cualquier acto de reproducción, distribución, comunicación pública y/o transformación total o parcial requiere el consentimiento expreso y escrito de aquéllos. Cualquier enlace al texto completo de estos documentos deberá hacerse a través de la URL oficial de éstos en Dialnet. Más información: https://dialnet.unirioja.es/info/derechosOAI | INTELLECTUAL PROPERTY RIGHTS STATEMENT: Full text documents hosted by Dialnet are protected by copyright and/or related rights. This digital object is accessible without charge, but its use is subject to the licensing conditions set by its authors or editors. Unless expressly stated otherwise in the licensing conditions, you are free to linking, browsing, printing and making a copy for your own personal purposes. All other acts of reproduction and communication to the public are subject to the licensing conditions expressed by editors and authors and require consent from them. Any link to this document should be made using its official URL in Dialnet. More info: https://dialnet.unirioja.es/info/derechosOAI</dc:rights>

   </oai_dc:dc>